BR112022018936A2 - Composições de anticorpo anti-cd6 e métodos para tratar e reduzir efeitos negativos de um coronavírus que inclui covid-19 - Google Patents

Composições de anticorpo anti-cd6 e métodos para tratar e reduzir efeitos negativos de um coronavírus que inclui covid-19

Info

Publication number
BR112022018936A2
BR112022018936A2 BR112022018936A BR112022018936A BR112022018936A2 BR 112022018936 A2 BR112022018936 A2 BR 112022018936A2 BR 112022018936 A BR112022018936 A BR 112022018936A BR 112022018936 A BR112022018936 A BR 112022018936A BR 112022018936 A2 BR112022018936 A2 BR 112022018936A2
Authority
BR
Brazil
Prior art keywords
methods
treat
antibody compositions
negative effects
corona virus
Prior art date
Application number
BR112022018936A
Other languages
English (en)
Portuguese (pt)
Inventor
Nair Pradip
Enrique Montero Casimiro Jose
Mazumdar Shaw Kiran
Bughani Usha
Nilkanth Athalye Sandeep
Subbaraman Ramakrishnan Melarkode
Crombet Ramos Tania
León Monzón Kalet
Ramos Suzarte Mayra
Original Assignee
Biocon Ltd
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Biocon Ltd, Ct Inmunologia Molecular filed Critical Biocon Ltd
Publication of BR112022018936A2 publication Critical patent/BR112022018936A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022018936A 2020-04-04 2021-04-03 Composições de anticorpo anti-cd6 e métodos para tratar e reduzir efeitos negativos de um coronavírus que inclui covid-19 BR112022018936A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
BR112022018936A2 true BR112022018936A2 (pt) 2022-12-06

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018936A BR112022018936A2 (pt) 2020-04-04 2021-04-03 Composições de anticorpo anti-cd6 e métodos para tratar e reduzir efeitos negativos de um coronavírus que inclui covid-19

Country Status (15)

Country Link
US (1) US20230151107A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526890A (cg-RX-API-DMAC7.html)
KR (1) KR20220165267A (cg-RX-API-DMAC7.html)
CN (1) CN115698071A (cg-RX-API-DMAC7.html)
AU (1) AU2021247258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174566A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002684A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014199A2 (cg-RX-API-DMAC7.html)
IL (1) IL296487A (cg-RX-API-DMAC7.html)
MX (1) MX2022012229A (cg-RX-API-DMAC7.html)
TW (1) TW202200202A (cg-RX-API-DMAC7.html)
WO (1) WO2021199006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210032B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il­6의 길항제
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
AU2020415307A1 (en) * 2019-12-24 2022-06-09 F. Hoffmann-La Roche Ag Method of treating virus infection using a TLR7 agonist

Also Published As

Publication number Publication date
JP2023526890A (ja) 2023-06-26
WO2021199006A1 (en) 2021-10-07
ZA202210032B (en) 2024-09-25
EP4126961A4 (en) 2024-07-17
CN115698071A (zh) 2023-02-03
TW202200202A (zh) 2022-01-01
AU2021247258A1 (en) 2022-11-10
KR20220165267A (ko) 2022-12-14
US20230151107A1 (en) 2023-05-18
EP4126961A1 (en) 2023-02-08
IL296487A (en) 2022-11-01
MX2022012229A (es) 2022-10-27
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08
CL2022002684A1 (es) 2023-03-24

Similar Documents

Publication Publication Date Title
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
EA202191736A1 (ru) Комбинированная терапия hbv
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
CO2022014199A2 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19
MX2018003594A (es) Anticuerpo anti-garp.
BR112022002351A2 (pt) Composições e métodos de anticorpo anti-cd39
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
MA46366B1 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
EP4445913A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
BR112023023030A2 (pt) Composições e métodos para o tratamento de depressão
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
BR112022000957A2 (pt) Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno
BR112023024772A2 (pt) Anticorpos anti-nkg2a e composições
BR112023016241A2 (pt) Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
BR112022021592A2 (pt) Anticorpo anti-igsf1 e uso do mesmo
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
PH12021551332A1 (en) Use of cocculus hirsutus extract for treating dengue
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
MX2016009887A (es) Procedimiento para el tratamiento de enfermedades infecciosas utilizando una composicion que comprende inmunoglobulina m (igm) derivada de plasma.
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2873 DE 27-01-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.